Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.0452W HIGH $9.13
Volume
454.41 K
Value Traded
1.72 M
Short % Float
5.34%
-0.5%Week
+12.71%1 Month
-9.17%3 Month
-6.16%6 Month
-90.21%5 Year
-60%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
157.64 M
EPS (TTM)
-0.93
P/E Ratio
-
Ent. Value
52.10 M
Total Shares
26.54 M
Float Shares
25.56 M
Insiders
3.70%
Institutions
73.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Inogen, Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inogen, Inc
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
Past FDA Catalysts and PDUFA Decisions
How INGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Inogen, Inc is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every INGN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Smith Kevin P.Officer (EVP, Bus Dev, GC & Sec) | Option | 18,136 41,643 held | $0.00 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 1 % (-16.7 %) | 5.45 M | 845.18 K |
INGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INGN ranks across every disease it competes in
Competitive Position is a premium feature
See how INGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINGN News
INGN▲ +13.5%on this news
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
Inogen has announced the divestiture of its U.S. oxygen rental business to Rotech. This strategic move is aimed at streamlining operations and allowing Inogen to concentrate on its core business areas. The transaction is expected to benefit both companies, with Rotech taking over a well-established rental service.
Read more →INGN▼ -6.8%on this news
Inogen Announces Second Quarter 2026 Financial Results
Inogen reported a revenue of $95.1 million for the second quarter of 2026. The company has also increased its full-year adjusted EBITDA guidance to approximately $4.0 million, indicating a positive financial outlook. This performance reflects strong operational results and confidence in future growth.
Read more →INGNInogen to Report Second Quarter 2026 Financial Results on August 6, 2026
Inogen has announced that it will report its financial results for the second quarter of 2026 on August 6, 2026. This announcement is part of the company's regular financial reporting schedule. The report will provide insights into Inogen's performance during this period.
Read more →INGNInogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen has announced the appointment of Andy Reding as the new Chief Operating Officer. This strategic move is expected to leverage Reding's extensive experience in the industry to improve operational efficiencies and drive growth within the company. The leadership change reflects Inogen's commitment to strengthening its management team.
Read more →INGNInogen Announces First Quarter 2026 Financial Results
Inogen, Inc. reported a 3.4% increase in revenue for Q1 2026 compared to the same quarter in the previous year, exceeding internal forecasts. The company reiterated its full-year guidance, projecting continued growth driven by international demand for portable oxygen concentrators and new product launches. However, despite revenue growth, Inogen recorded an increased net loss and negative adjusted EBITDA, indicating ongoing challenges in the domestic market. The firm has initiated several strategic initiatives, including a share repurchase program and new product developments, to bolster future growth prospects.
Read more →INGNInogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc. has appointed Vafa Jamali as an independent director to its Board, effective at the upcoming 2026 Annual Meeting. Jamali, a seasoned medical device executive, is expected to contribute valuable insights and strategic leadership, benefiting Inogen’s transformation into a diversified respiratory care platform. His history of driving growth and profitability at established companies encourages optimism about Inogen's future performance. The announcement also includes a cooperation agreement with Kent Lake Partners to support the company's strategic initiatives.
Read more →INGNInogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This announcement reflects the company's compliance with regulatory requirements for equity awards. Further details on the specific grants or their implications were not provided in the article.
Read more →INGNInogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque
Inogen, Inc. has announced several key leadership appointments designed to support its next phase of growth. Jason Richardson has been appointed as Chief Financial Officer, succeeding Michael Bourque, who will continue in an advisory role. Dominic Hulton is named Chief Marketing Officer, aimed at enhancing the company's global brand and expanding customer engagement. Corey Moritz also joins as Vice President of U.S. Business to Business Sales, bringing extensive experience in commercial transformation and revenue growth. The management changes come as the company reaffirms its financial outlook for the first quarter and full year of 2026.
Read more →INGNInogen Announces $30 Million Share Repurchase Program
Inogen, Inc. has announced a $30 million share repurchase program authorized by its Board of Directors. This initiative is intended to enhance shareholder value and reflects the company's confidence in its long-term growth strategy. The program will be financed through cash flow and existing reserves and is set to expire by December 31, 2027, or once the maximum amount is utilized.
Read more →INGNInogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook
Inogen, Inc. announced its financial results for the fourth quarter and full year of 2025, reporting a revenue growth of approximately 4% and an improved profitability with a GAAP net loss of $22.7 million. The company achieved a positive adjusted EBITDA for the first time since 2021 and introduced new products aimed at enhancing its market position. Looking ahead to 2026, Inogen anticipates continued growth with expected revenues ranging from $366 million to $373 million, although it warns of potential declines in U.S. rentals revenue due to changing reimbursement dynamics.
Read more →INGN▼ -11.7%on this news
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen, Inc. (Nasdaq: INGN) announced its preliminary revenue results for the fourth quarter and full year 2025, estimating fourth quarter revenue of around $82 million, reflecting a 2% year-over-year increase, and a total annual revenue of approximately $349 million, a 4% growth. The company is maintaining a focus on financial discipline and anticipates achieving positive adjusted EBITDA for the full year. Despite some delays in large customer orders pushing into 2026, Inogen reports ongoing progress in its business turnaround and product innovation.
Read more →INGN▼ -8.3%on this news
Inogen Announces Third Quarter 2025 Financial Results Delivered seventh consecutive quarter of mid-single-digit revenue growth
Inogen, Inc. reported its financial results for Q3 2025, achieving $92.4 million in revenue, a 4.0% year-over-year increase. This marks the seventh consecutive quarter of revenue growth. The company also posted a positive adjusted EBITDA of $2.3 million and reiterated its full-year revenue guidance of $354 million to $357 million. However, it reported a GAAP net loss of $5.3 million and a decline in gross margin compared to the previous year, highlighting some ongoing challenges.
Read more →INGN▼ -6.8%on this news· ran to +20% by day 3
Inogen Announces Second Quarter 2025 Financial Results Delivered strong top-line results; raising full year 2025 revenue expectations
Inogen, Inc. reported its financial results for the second quarter of 2025, highlighting a revenue of $92.3 million, marking a 4% year-over-year growth. The company announced the launch of its new oxygen concentrator, Voxi 5, and positive adjusted EBITDA for the second consecutive quarter. However, it also faced a GAAP net loss of $4.2 million and a decline in gross margin compared to last year. Due to strong performance in the first half of the year, Inogen has raised its full-year revenue guidance.
Read more →INGNInogen Announces First Quarter 2025 Financial Results
Inogen, Inc. has announced its financial results for the first quarter of 2025, showcasing a revenue increase to $82.3 million, up 5.5% from the previous year. The company's gross margin improved slightly, while operating expenses decreased significantly by 13.1%. However, despite these improvements, Inogen reported a net loss of $6.2 million. Moving forward, the company projects revenues for the full year to range between $352 million and $355 million, reflecting continued growth expectations.
Read more →INGNInogen Announces Fourth Quarter and Full Year 2024 Financial Results
Inogen, Inc. has reported its financial results for the fourth quarter and full year of 2024, highlighting revenue growth of 5.5% in Q4 and 6.4% for the year. The improvements are attributed to increased demand in both domestic and international business-to-business sales, although direct-to-consumer sales declined. The company anticipates continued growth in 2025, aided by a strategic collaboration with Yuwell, which enhances its global market potential.
Read more →INGNInogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West
Inogen, Inc. has announced the appointment of Mira Kirti Sahney to its Board of Directors, effective January 31, 2025, following the retirement of Tom West. Sahney brings significant management and operational experience from her previous roles in the medical device field. Inogen's Chairperson, Elizabeth Mora, expressed enthusiasm about Sahney's addition, highlighting her capabilities to advance the company’s position in respiratory care. The announcement emphasizes a period of transformation and growth for Inogen.
Read more →INGNInogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration with Yuwell
Inogen, Inc. has announced a strategic collaboration with Yuwell aimed at expanding its product portfolio and enhancing its innovation pipeline. This partnership will facilitate the distribution of Inogen's respiratory products in the United States and other regions, while also aiding the company's entry into the Chinese market. Additionally, Yuwell will invest approximately $27.2 million into Inogen, increasing its equity stake. The collaboration is expected to accelerate Inogen's growth and satisfy the needs of respiratory patients globally.
Read more →INGN▲ +8.2%on this news
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Inogen, Inc. has announced its preliminary revenue results for the fourth quarter and full year ending December 31, 2024. The company estimates Q4 revenue between $79 million and $80 million, reflecting a year-over-year growth of 4% to 5%. For the full year, Inogen expects revenue between $334.5 million and $335.5 million, surpassing previous guidance. The positive performance is attributed to strong business-to-business growth and new product launches aimed at enhancing patient care in respiratory therapy.
Read more →INGN▲ +6.2%on this news
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device GOLETA, Calif., –
Inogen, Inc. has announced that it received FDA 510(k) clearance for its SIMEOX 200 Airway Clearance Device, enabling it to market this innovative product for patients with chronic respiratory diseases. This next-generation device enhances bronchial drainage through high frequency oscillatory vibrations and is aimed at conditions such as COPD and Cystic Fibrosis. Inogen plans to initiate a limited launch of the SIMEOX 200 in targeted sites in 2025, leveraging its established network of healthcare providers for broad distribution. The approval represents a significant step in expanding patient access to respiratory therapies.
Read more →INGNInogen Announces Third Quarter 2024 Financial Results GOLETA, Calif., –
Inogen, Inc. announced its financial results for the third quarter of 2024, reporting a revenue increase of 5.8% compared to the same quarter last year, amounting to $88.8 million. Significant improvements were seen in gross margin and a substantial decrease in operating expenses due to the absence of a one-time goodwill impairment charge. The adjusted EBITDA showed a positive turnaround, reflecting effective cost management and strategic initiatives. However, the company still reported a GAAP net loss, indicating ongoing challenges in the direct-to-consumer market segment.
Read more →About Inogen, Inc
Headquarters500 CUMMINGS CENTER, BEVERLY, MA, 01915
BIOPHARMAWATCH ELITE PLUS
Trade the next INGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime